Related Experiment Video
Updated: Apr 30, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.5K
Ibrutinib.
Mark-Alexander Schwarzbich1, Matthias Witzens-Harig
1Universität Heidelberg, Heidelberg, Germany.
Summary
Ibrutinib effectively targets Bruton
Area of Science:
- Oncology
- Pharmacology
Background:
- Abnormal B-cell receptor (BCR) signaling drives B-cell malignancies.
- Bruton's tyrosine kinase (BTK) is crucial in BCR signaling pathways.
- Ibrutinib is a potent, selective, irreversible BTK inhibitor.
Purpose of the Study:
- To review the structure, mechanism of action, and toxicities of ibrutinib.
- To present preclinical and clinical data on ibrutinib's efficacy in B-cell malignancies.
Main Methods:
- Review of preclinical studies.
- Analysis of Phase I and II clinical trial data for ibrutinib.
Main Results:
- Ibrutinib demonstrates high efficacy and tolerability in B-cell malignancies.
- Effective in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma.
- Notably lacks myelosuppression, a common side effect of other treatments.
Conclusions:
- Ibrutinib shows significant promise as a novel therapeutic agent for B-cell malignancies.
- Further Phase III trials are necessary to establish its definitive role in clinical practice.
Related Concept Videos
02:56Treatment Resistent Cancers
1.1K
1.1K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:57Targeted Cancer Therapies
1.4K
1.4K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:50Combination Therapies and Personalized Medicine
1.5K
1.5K